baber/WOPTO huggingface dataset:
Patent NZ-561374-A (NZ)
Title: Polymyxin B analogs for LPS detoxification
Inventor: PORRO MASSIMO
Filed: 2006-04-10
Abstract: Disclosed is a SAEP II peptide dimer of formula (I) NH2-A-Cys1-B-Cys2-C-COOH NH2-A-Cys1-B-Cys2-C'-COOH wherein the two Cys1 residues are linked together through a disulphide bond and the two Cys2 residues are linked together through a disulphide bond; or formula (II) NH2-A-Cys1-B-Cys2-C-COOH HOOC-C'-Cys2-B'-,Cys1-A'-NH2 wherein the Cys1 residues are linked to the Cys2 residues through a disulphide bond ; wherein A and A' independently are a peptide moiety of from 2 to 5, amino acid residues, in which at least 2 amino acid residues, are independently selected from Lys, Hyl (hydroxy-Lysine), Arg and His; wherein B and B' independently are a peptide moiety of from 3 to 7, amino acid residues, which comprise at least two, preferably three amino acid residues independently selected from Val, Leu, Ile.Phe, Tyr andTrp ; and wherein C and C' are optional and are independently an amino acid residue or a peptide moiety of from 2 to 3 amino acid residues; provided that the cationic amino acid residues I hydrophobic amino acid residues ratio (cat/hydroph ratio) is from 0.4 to 2. Also disclosed are the use of said peptide dimer in the manufacture of medicaments and a process for producing said peptide dimer.
Patent NZ-561823-A (NZ)
Title: Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
Inventor: HANON EMMANUEL JULES
IPC: A61K39/145
Filed: 2006-03-21
Abstract: The disclosure relates to the use of (a) an influenza virus or antigenic preparation thereof. and (b) an oil-in water emulsion adjuvant in the manufacture of an immunogenic composition for inducing at least one of i) an improved CD4 T-cell immune response, ii) an improved B-memory cell response against said virus or antigenic composition in a human wherein said oil-in-water emulsion comprises a metabolisable oil, a sterol and/or alpha-tocopherol and an emulsifying agent. Also disclosed is a method of designing a vaccine of influenza comprising selecting an influenza virus antigen and combining said antigen with an said oil-in water adjuvant.
Patent NZ-562242-A (NZ)
Title: Controlling a heater by comparing an assessed electrical characteristic to predicted behaviour
Inventor: HARRIS CHRISTOPHER KELVIN
IPC: E21B36/04
Filed: 2006-04-21
Abstract: Disclosed is a method for controlling a heater. The method comprises providing a heater, assessing an electrical characteristic of the heater, comparing the characteristic to predicted behaviour of the characteristic, and controlling the heater based on the comparison. The heater comprises a ferromagnetic conductor, an electrical conductor which is a jacket that at least partly surrounds the ferromagnetic conductor and is coupled to the ferromagnetic conductor, and an inner electrical conductor partially surrounded by and electrically coupled to the ferromagnetic conductor. The inner electrical conductor comprises a strength member that provides mechanical strength to support the heater, the strength member having a core with dispersion strengthened copper and/or copper with tungsten fibre. An electromagnetic field produced by time-varying current flow in the ferromagnetic conductor confines a majority of the flow of the electrical current to the electrical conductor at temperatures below or near a Curie temperature of the ferromagnetic conductor. The heater is configured to allow heat to transfer from the heater to a part of the subsurface formation to a temperature above the ambient temperature of the part of the formation.
Patent NZ-570110-A (NZ)
Title: Plant treatment material
Inventor: TOYE JONATHAN DALLAS
IPC: A01G13/02
Filed: 2004-07-22
Abstract: A reflective woven ground cover sheet material that is woven from warp 45 and weft 46 tapes with some of the warp 45 and weft 46 tapes spaced away from each other. The spacing apart of the warp 45 and weft 46 tapes is such that the percentage of the surface area of the material that is covered by the apertures 47 between the warp 45 and weft 46 tapes is at least 2%.
Patent NZ-570484-A (NZ)
Title: Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers
Inventor: DIWAN ANIL
IPC: C08F8/34
Filed: 2006-01-19
Abstract: Disclosed is a comb polymer with the structure as depicted. The back bone consists of water-soluble polymer blocks (A); branch-point moieties (B) and hydrophobic side chains (C). Where each instance of C is independently chosen from the group consisting of linear hydrocarbons optionally substituted with one or more hydrophilic substituents, polycyclic hydrocarbons optionally substituted with one or more hydrophilic substituents, hydrophobic amino acids, peptides and polymers; wherein n ranges from 3 to about 100; and wherein, on average p is greater than 1 and less than 4. The polymer can further comprise one or more reactive functional groups X attached to each branch-point (B). Also disclosed is a pharmaceutical composition comprising the comb polymer and a method of increasing the solubility of a substance by contacting the substance with the polymer.
Patent NZ-576658-A (NZ)
Title: Treatments and kits for creating transparent renewable surface protective coatings using fumed silica particles
Inventor: RUSSELL JODI LYNN
IPC: B32B3/00
Filed: 2006-10-10
Abstract: Disclosed is a treatment composition for forming a detachable and renewable protective coating on a receptive surface comprising: (i) 0.05 to 5.0 percent by weight of a plurality of hydrophobically modified fumed silica particles having a median particle size of between 100 and 4,000 nanometers, and (ii) 99.95 to 5 percent by weight of a volatile solvent; wherein said treatment composition when applied to said receptive surface deposits said protective coating on said receptive surface, wherein said protective coating provides dirt- and water-repellency to said receptive surface, and wherein said coating is substantially transparent and results in a change of less than 3.0 Delta E units to said receptive surface measured before and after deposition of said coating; and wherein said treatment composition is obtained by dilution of a process composition comprising the plurality of hydrophobically modified fumed silica particles obtained by a process described in the specification.
Patent NZ-578329-A (NZ)
Title: Igf1r inhibitors for treating cancer
Inventor: WANG YAN
IPC: A61K45/06
Filed: 2007-12-11
Abstract: Provided is the use of an isolated antibody or antigen-binding fragment thereof comprising specified light and heavy immunoglobulin chain sequences for preparing a medicament for treating or preventing various types of cancers, leukemiae, lymphomas , tumours and sarcomas. The medicament can be combined with various cytotoxic and chemotherapeutic agents.
Patent NZ-578600-A (NZ)
Title: A mask system for apnea vent holes in flexible shell and cushion as integral unit
Inventor: FU TIMOTHY TSUN-FAI
IPC: A61M16/08
Filed: 2004-04-30
Abstract: A mask system is disclosed for treating sleep disorder breathing having a flexible shell and cushion unit having a central aperture, a rigid frame engageable with the shell and cushion unit, a rigid ring-shaped member engageable with the shell aperture peripheral wall, a rotatable elbow engageable with the rigid ring-shaped member, vent holes being provided in the shell and cushion unit, and headgear attachment points on the rigid frame.
Patent NZ-579431-A (NZ)
Title: Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
Inventor: CAO BIN
IPC: A61P25/24
Filed: 2008-03-06
Abstract: Disclosed is a dihydro and tetrahydro oxazolopyrimidinones compound of formula (I) wherein the substituents are as disclosed in the description. Examples of compounds of formula (I) include: 2-{ 4-isopropyl-phenoxymethyl)-2,3-dihydro-oxazoIo[3,2-a]pyrimidin-7-one; 2-{ 3-tert-butyl-phenoxymethyl)-2,3-dihydro-oxazolo[3,2-a ]pyrimidin-7-one and 2-[ 4-(1-methyl-l-phenyl-ethyl)-phenoxymethyl]-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7 -one. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and the use of a compound of formula (I) for the preparation of a pharmaceutical composition for modulating one or more metabotropic glutamate receptor functions for treating neurological or psychiatric disorders for treating anxiety, migraine, schizophrenia, epilepsy and pain.
Patent NZ-589434-A (NZ)
Title: Dual variable domain immunoglobulins and uses thereof
Inventor: GHAYUR TARIQ
IPC: C07K16/20
Filed: 2009-06-03
Abstract: Provides is a binding protein comprising first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein VD is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; XI is a linker with the proviso that it is not CHI; X2 is an Fc region; n is 0 or 1; and wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein VD 1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; XI is a linker with the proviso that it is not CHI; X2 does not comprise an Fc region; nis 0 or 1; and wherein the binding protein binds TNF and IL-17A, wherein the heavy and light chain six CDRs have defined sequences. The antibodies can be used for various diseases, including immunological conditions and cancers.
Patent NZ-590070-A (NZ)
Title: Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
Inventor: PLETTENBURG OLIVER
IPC: A61P25/00
Filed: 2009-06-19
Abstract: Disclosed is a compound of the formula (I) e.g. 6-[4-(1-amino-propyl)-4-(4-fluoro-phenyl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one, wherein R1 - R 14, r, n, m, s, L is defined in the specification and their stereoisomeric and/or tautomeric forms and/or their pharmaceutically acceptable salts for the treatment and/or prevention of hypertension, pulmonary hypertension, ocular hypertension, retinopathy, glaucoma, peripheral circulatory disorder, peripheral arterial occlusive disease (PAOO), coronary heart disease, angina pectoris, heart hypertrophy, heart failure, ischemic diseases, ischemic organ failure (end organ damage), fibroid lung, fibroid liver, liver failure, nephropathy, renal failure, fibroid kidney, renal glomerulosclerosis, organ hypertrophy, asthma, chronic obstructive pulmonary disease (COPO), adult respiratory distress syndrome, thrombotic disorders, stroke, cerebral vasospasm, cerebral ischemia, pain, neuronal degeneration, spinal cord injury, Alzheimer's disease, premature birth, erectile dysfunction, endocrine dysfunctions, arteriosclerosis, prostatic hypertrophy, diabetes and complications of diabetes, metabolic syndrome, blood vessel restenosis, atherosclerosis, inflammation, autoimmune diseases, AIDS, osteopathy, infection of digestive tracts with bacteria, sepsis or cancer development and progression.
Patent NZ-592113-A (NZ)
Title: Highly concentrated drug particles, formulations, suspensions and uses thereof
Inventor: ALESSI THOMAS R
IPC: A61K9/00
Filed: 2009-10-14
Abstract: Disclosed is a pharmaceutical suspension formulation comprising, a particle formulation comprising, about 25 wt percent to about 80 wt percent drug, wherein the drug is a protein, and about 75 wt percent to about 20 wt percent of one or more additional component, wherein the one or more additional component comprises antioxidant e.g. methionine, carbohydrate e.g. sucrose, and buffer e.g. citrate, and the ratio of drug:antioxidant:carbohydrate:buffer is between about 2-20: 1-5: 1-5: 1-10; and a non-aqueous, single-phase suspension vehicle comprising one or more polymer and one or more solvent.
Patent NZ-592915-A (NZ)
Title: Cableway with chairs having second adjustment device for locking safety bar if still not locked after a first such device
Inventor: BECK MARKUS
IPC: B61B12/00
Filed: 2011-05-18
Abstract: The cableway has a first adjusting device 5 and a sensor 50 for locking and detecting locking of the safety bar of a chair 3. A second adjusting device 6 and sensor 60 are also provided to allow for either the safety bar 3 being locked after leaving device 5, or not being locked by device 5.
Patent NZ-593550-A (NZ)
Title: ANTI-Siglec-15 ANTIBODY
Inventor: TAKIZAWA TAKESHI
IPC: A01N29/06
Filed: 2010-04-07
Abstract: NZ 593550 Disclosed is an antibody which specifically binds to a polypeptide consisting of amino acid residues 39 to 165 of an amino acid sequence represented by SEQ ID NO: 2, as defined in the complete specification. The disclosed antibody inhibits osteoclast formation and/or osteoclastic bone reabsorption.
Patent NZ-594276-A (NZ)
Title: Easy adhesion polyamide film and production method therefor
Inventor: OKUZU TAKAYOSHI
IPC: B29C55/12
Filed: 2010-03-24
Abstract: 594276 The disclosure relates to a highly adhesive polyamide film comprising a substrate polyamide film and a primary layer containing an anionic water-dispersible polyurethane resin. The substrate polyamide film is coated with the primary layer, biaxially stretched then subjected to oriented crystallisation by heat treating to form the finished product. The primer layer has a thickness of between 0.025 and 0.250 µm and the anionic water-dispersible polyurethane resin has a film elasticity of at least 250% and a tensile strength of at least 20 MPa. The highly adhesive polyamide film generates no more than 0.50 µg/g of volatile base components when heat treated for 10 minutes at 200°C under a helium atmosphere. The disclosure also relates to a laminate using the polyamide film and a production method for forming it.
Patent NZ-596952-A (NZ)
Title: Apparatus which automatically energises a lower packer of a telescoping joint of a drilling apparatus if upper packer pressure is lost
Inventor: RODGER BRADLEY RAY
IPC: E21B47/00
Filed: 2008-12-22
Abstract: Disclosed is a riser slip joint circuit. The circuit has an upper packer and a lower packer, and first, second and third conduits with associated first, second, and third pressures. The second conduit is connected to the first conduit and the upper packer. The circuit also has a differential pressure valve connected to the first, second, and third conduits, and the differential pressure valve allows the third pressure to energize the lower packer when the second pressure is operationally lower than the first pressure.
Patent NZ-601628-A (NZ)
Title: Helicopter cargo basket mounting assembly and method of using same
Inventor: STOCKER ALAN
IPC: B64C27/04
Filed: 2011-02-01
Abstract: 601628 A mounting assembly (20) for mounting an external cargo basket (12) onto a helicopter and a method of using the mounting assembly is disclosed. The mounting assembly comprises a plurality of connectors - corresponding male and female connectors being positioned on the helicopter (30, 39) and on the basket (14, 37), one of said corresponding connectors being an articulating connector. The cargo basket is connected to the helicopter by first connecting the articulating connector then pivoting and rotating the cargo basket using the articulating connector so as to align and connect the remaining connections. The basket is mounted to the helicopter cross tubes (8) by way of the mounting assembly.
Patent NZ-603450-A (NZ)
Title: Biologic female contraceptives
Inventor: TEITELBAUM RACHEL
IPC: A61K39/395
Filed: 2011-05-04
Abstract: Disclosed is a genetically engineered commensal bacterium of the female genital tract, wherein said genetically engineered bacterium is a Lactobacillus engineered to express an anti-sperm agent such as a scFv antibody or fragment thereof.
Patent NZ-615193-A (NZ)
Title: Dendrimer scaffolds for pharmaceutical use
Inventor: RENDLE PHILLIP MARTIN
IPC: C08L79/02
Filed: 2012-09-05
Abstract: Disclosed are 2-(bis(2-(2-aminoethoxy)ethyl)amino acetic acid derived dendrimer compounds of the general formula (I), or salts thereof, and which include a 2-(2-aminoethoxy)ethyl-amine repeat unit; wherein the variables are as defined herein. Also disclosed is pharmaceutical composition comprising a compound of formula (I) together with an active agent (such as anti-cancer agents, analgesic agents, anti-inflammatory agents, targeting agents, anti-malarial drugs, antibiotics including penicillins, sulfonamides, macrolides, tetracyclines, quinolones, cephalosporins, aminoglycosides and glycopeptides, and anti-viral agents) attached to, or encapsulated within, the compound of formula (I) together with suitable carriers and/or excipients.
Patent NZ-617517-A (NZ)
Title: A retention system for a pliable sheet
Inventor: BRIAN LIONEL ZWAR
IPC: E06B9/52
Filed: 2013-11-12
Abstract: Disclosed is a retention system for a pliable sheet as part of a door or window frame assembly. The system comprises a support comprising a channel having an opening, and a flexible or elastomeric spline for capturing a portion of the pliable sheet between itself and an interior of the channel. An attachment cover lid includes a projection, where the attachment is securable with respect to the support by engagement between the support and the attachment which is independent or separate of the channel, and in use, the attachment extends across at least a portion of the opening to the channel to conceal the channel. The projection is located adjacent to the spline and is directed into the channel to bear against the spline and prevents escape of the spline therefrom. The projection is substantially continuous along the length of the attachment.
Patent NZ-620261-A (NZ)
Title: Methods of modifying antibodies, and modified antibodies with improved functional properties
Inventor: URECH DAVID
IPC: C12N15/13
Filed: 2008-06-25
Abstract: Disclosed is a method of engineering an immunobinder, the immunobinder comprising a human Vlambda1 family light chain variable region, or fragment thereof, the Vlamda1 family light chain variable region comprising VL framework residues, the method comprising: A) selecting one or more amino acid positions within the Vlambda1 framework residues; and B) mutating the one or more amino acid positions selected for mutation, wherein the mutating comprises one or more substitutions selected from the group consisting of: wherein if the one or more light chain amino acid positions selected for mutation are of a human Vlambda1 family light chain variable region, the mutating comprises one or more substitutions selected from the group consisting of: (i) leucine (L), serine (S) or glutamic acid (E) at amino acid position 1 using AHo or Kabat numbering system; (ii) alanine (A), proline (P), isoleucine (I) or tyrosine (Y) at amino acid position 2 using AHo or Kabat numbering system; (iii) valine (V) or methionine (M) at amino acid position 4 using AHo or Kabat numbering system; (iv) glutamic acid (E) at amino acid position 7 using AHo or Kabat numbering system; (v) alanine (A) at amino acid position 11 using AHo or Kabat numbering system; (vi) threonine (T) or serine (S) at amino acid position 14 using AHo or Kabat numbering system; (vii) histidine (H) at amino acid position 46 using AHo numbering system (amino acid position 38 using Kabat numbering system); (viii) threonine (T), serine (S), asparagine (N), glutamine (Q) or proline (P) at amino acid position 53 using AHo numbering system (amino acid position 45 using Kabat numbering system); (ix) arginine (R) or glutamine (Q) at amino acid position 82 using AHo numbering system (amino acid position 66 using Kabat numbering system); (x) glycine (G), threonine (T) or aspartic acid (D) at amino acid position 92 using AHo numbering system (amino acid position 74 using Kabat numbering system); and (xi) valine (V), threonine (T), histidine (H) or glutamic acid (E) at amino acid position 103 using AHo numbering (amino acid position 85 using Kabat numbering).
Patent NZ-622398-A (NZ)
Title: Antisense modulation of gcgr expression
Inventor: FREIER SUSAN M
IPC: C12N15/113
Filed: 2012-09-20
Abstract: Disclosed is a compound comprising a modified oligonucleotide 12 to 30 linked nucleosides in length and having a nucleobase sequence comprising an at least 12 nucleobase portion of SEQ ID NO: 11 (GGTTCCCGAGGTGCCCA), and related use in the manufacture of a medicament for treatment a disease or condition associated with GCGR or an increase in blood glucose levels.
Patent NZ-627036-A (NZ)
Title: Piperidino-pyrimidine derivatives for the treatment of viral infections
Inventor: RABOISSON PIERRE JEAN-MARIE BERNARD
IPC: C07D471/04
Filed: 2013-02-07
Abstract: Disclosed are 2,4-diamino-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine derivatives and analogues of the general formula (I), or a pharmaceutically acceptable salt, tautomer, solvate or polymorph thereof, wherein: A is selected from the group consisting of CH2, NCOR2, CHR3 and CR3R3; B is selected from the group consisting of CH2, NCOR4, CHR3 and CR3R3; with the proviso that when A is NCOR2 then B is not NCOR4 and with the proviso that A and B are not both selected from CH2, CHR3 or CR3R3; X is selected from CH2 or CHR5; R1 is selected from alkyl optionally substituted with one or more of the following: alkyl, cycloalkyl, hydroxyl, hydroxyalkyl, amino, nitrile, alkoxy, alkoxy-alkyl, carboxylic acid, carboxylic ester or carbamate; R2 is selected from substituted and unsubstituted alkyl, cycloalkyl, heterocycle, aryl, heteroaryl, alkylheteroaryl, each of which is optionally substituted by one or more substituents independently selected from halogen, hydroxyl, amino, alkyl, dialkylamino, alkylamino, alkyl, alkoxy, cycloalkyl, carboxylic acid, carboxylic ester, carboxylic amide, heterocycle, aryl, alkenyl, alkynyl, alkylaryl, heteroaryl, alkylheteroaryl or nitrile; R3 is selected from hydrogen, substituted and unsubstituted alkyl, alkoxy, alkoxy-alkyl, cycloalkyl, heterocycle, bicyclic heterocycle, alkylaryl, heteroaryl, alkylheteroaryl each of which is optionally substituted by one or more substituents independently selected from halogen, hydroxyl, amino, alkyl, dialkylamino, alkylamino, alkyl, alkoxy, cycloalkyl, carboxylic acid, carboxylic ester, carboxylic amide, heterocycle, aryl, alkenyl, alkynyl, alkylaryl, heteroaryl, alkylheteroaryl or nitrile; R4 is selected from substituted or unsubstituted alkyl, alkoxy, alkoxy-alkyl, aryl or cycloalkyl each of which is optionally substituted by heterocycle, nitrile, alkylheteroaryl or heteroaryl; and wherein R5 is selected from bicyclic heterocycle, aryl, heteroaryl, each of which is optionally substituted by one or more substituents independently selected from halogen, hydroxyl, amino, alkyl, dialkylamino, alkylamino, alkyl, alkoxy, cycloalkyl, carboxylic acid, carboxylic ester, carboxylic amide, heterocycle, aryl, alkenyl, alkynyl, alkylaryl, heteroaryl, alkylheteroaryl or nitrile. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, solvate or polymorph thereof as defined above, together with one or more pharmaceutically acceptable excipients, diluents or carriers, for the treatment of viral infections, immune or inflammatory disorders, whereby the modulation, or agonism of toll-like-receptors (TLRs) is involved.
Patent NZ-627973-A (NZ)
Title: Certain amino-pyridazines, compositions thereof, and methods of their use
Inventor: MUCI ALEX R
IPC: C07D513/04
Filed: 2011-04-22
Abstract: Provided are amino-pyridazine compounds of general formula I, where the variables are as defined in the specification. Examples of the compounds include N-(5-(6-(2-(4-Fluorophenyl)-2-methylpropylamino)pyridazin-3-yl)-1H-indazol-3-yl)acetamide and 4-Fluoro-3-(6-(((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyridazin-3-yl)benzamide. The compounds modulate the troponin complex of the fast skeletal muscle sarcomere. The compounds may be useful in the treatment of neuromuscular disorders, conditions of muscle wasting, muscular myopathies, rehabilitation related deficits, peripheral vascular disease, peripheral arterial disease, frailty, muscle atrophy and fatigue, metabolic syndrome, chronic fatigue syndrome and obesity. Further provided are processes for the preparation of the compounds, compositions comprising the compounds and uses thereof.